CDT Equity Inc. CDT
Biotechnology: Pharmaceutical Preparations · IPO 2022 · data as of November 13, 2026
CDT Equity Inc. (CDT) is a healthcare company listed in the US with a market value of about $407552.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -1212%.
About CDT Equity
CDT Equity is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2022. It was profitable in 0 of the last 4 years in our data. Its share count rose by 26580% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Net income | -$39M | -$18M | -$535000 | -$5M |
| Free cash flow | — | -$10M | — | — |
| EPS (diluted) | $-1177.89 | $-61598.62 | $-26762.96 | $-39004.31 |
| Net margin | — | — | — | — |
| ROIC | — | — | -1212.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does CDT Equity pay a dividend?
Not currently.
Is CDT Equity a good stock to buy?
We do not give buy or sell advice. CDT Equity scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.